Repositioning Candidate Details
| Candidate ID: | R0277 |
| Source ID: | DB00775 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Tirofiban |
| Synonyms: | (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine |
| Molecular Formula: | C22H36N2O5S |
| SMILES: | CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O |
| Structure: |
|
| DrugBank Description: | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. |
| CAS Number: | 144494-65-5 |
| Molecular Weight: | 440.597 |
| DrugBank Indication: | For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. |
| DrugBank Pharmacology: | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. When administered intravenously, tirofiban inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the recommended regimen, >90% inhibition is attained by the end of the 30-minute infusion. Tirofiban has been recently shown in patients with unstable angina to reduce ischemic events at 48 hours following infusion when compared to standard heparin therapy. |
| DrugBank MoA: | Tirofiban is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. Platelet aggregation inhibition is reversible following cessation of the infusion of tirofiban. |
| Targets: | Integrin alpha-IIb antagonist; Integrin beta-3 antagonist |
| Inclusion Criteria: | Therapeutic strategy associated |
